Treatment with SGLT2 inhibitors in patients with diabetes could provide better glycaemic control and insulin sensitivity and reduce arterial blood pressure, arterial stiffness, body weight, and visceral fat27–30. Here, SLC5A2 is linked to diabetes mellitus.